MedTrace Logo

Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

NCT05433285 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4050

Last updated 2023-11-29

No results posted yet for this study

Summary

Observer-blind, randomized, active-controlled prospective intervention study

Conditions

Interventions

BIOLOGICAL

COVID-19 Protein Subunit Recombinant Vaccine

SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma

BIOLOGICAL

Active Comparator

Covovax® COVID-19 vaccine is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 betacoronavirus

Sponsors & Collaborators

  • Fakultas Kedokteran Universitas Indonesia

    collaborator OTHER

  • Faculty of Medicine Universitas Diponegoro

    collaborator UNKNOWN

  • Faculty of Medicine Universitas Andalas

    collaborator UNKNOWN

  • Faculty of Medicine Universitas Hassanudin

    collaborator UNKNOWN

  • PT Bio Farma

    lead INDUSTRY

Principal Investigators

  • Prof. Dr. Soedjatmiko SpA(K), MSi, MD · Fakultas Kedokteran Universitas Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-07
Primary Completion
2022-08-05
Completion
2023-08-31

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05433285 on ClinicalTrials.gov